GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Omeros Corp (NAS:OMER) » Definitions » Debt-to-EBITDA

Omeros (Omeros) Debt-to-EBITDA : -1.85 (As of Dec. 2023)


View and export this data going back to 2009. Start your Free Trial

What is Omeros Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Omeros's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $5.16 Mil. Omeros's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $231.30 Mil. Omeros's annualized EBITDA for the quarter that ended in Dec. 2023 was $-128.08 Mil. Omeros's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was -1.85.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Omeros's Debt-to-EBITDA or its related term are showing as below:

OMER' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -2.16   Med: -1.48   Max: -0.46
Current: -1.65

During the past 13 years, the highest Debt-to-EBITDA Ratio of Omeros was -0.46. The lowest was -2.16. And the median was -1.48.

OMER's Debt-to-EBITDA is ranked worse than
100% of 273 companies
in the Biotechnology industry
Industry Median: 1.3 vs OMER: -1.65

Omeros Debt-to-EBITDA Historical Data

The historical data trend for Omeros's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Omeros Debt-to-EBITDA Chart

Omeros Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.36 -1.60 -2.04 -2.16 -1.65

Omeros Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.25 -2.71 -2.37 -1.96 -1.85

Competitive Comparison of Omeros's Debt-to-EBITDA

For the Biotechnology subindustry, Omeros's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Omeros's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Omeros's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Omeros's Debt-to-EBITDA falls into.



Omeros Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Omeros's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(5.16 + 231.298) / -143.156
=-1.65

Omeros's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(5.16 + 231.298) / -128.076
=-1.85

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.


Omeros  (NAS:OMER) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Omeros Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Omeros's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Omeros (Omeros) Business Description

Traded in Other Exchanges
Address
201 Elliott Avenue West, Seattle, WA, USA, 98119
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The lead drug candidate in pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.
Executives
Demopulos Gregory A Md director, 10 percent owner, officer: Chairman, CEO & President 201 ELLIOTT AVENUE WEST, SEATTLE WA 98119
Demopulos Peter A Md director 201 ELLIOTT AVENUE WEST, SEATTLE WA 98119
Arnold C Hanish director 201 ELLIOTT AVENUE WEST, SEATTLE WA 98119
Thomas J. Cable director 201 ELLIOTT AVENUE WEST, SEATTLE WA 98119
Diana T. Perkinson director 201 ELLIOTT AVENUE WEST, SEATTLE WA 98119
Michael A Jacobsen officer: VP Finance and CAO 201 ELLIOTT AVENUE WEST, SEATTLE WA 98119
Kurt Zumwalt director 201 ELLIOTT AVENUE WEST, SEATTLE WA 98119
Peter B Cancelmo officer: See Remarks 201 ELLIOTT AVENUE WEST, SEATTLE WA 98119
Thomas F. Bumol director 201 ELLIOT AVENUE WEST, SEATTLE WA 98119
Marcia S. Kelbon officer: VP Patent and General Counsel 201 ELLIOTT AVENUE WEST, SEATTLE WA 98119
Ray Aspiri director 201 ELLIOTT AVENUE WEST, SEATTLE WA 98119
Hood Leroy E. Md Phd director 201 ELLIOTT AVENUE WEST, SEATTLE WA 98119
Rajiv Shah director C/O ARCADIA BIOSCIENCES, INC., 202 COUSTEAU PLACE, SUITE 105, DAVIS CA 95618
Daniel K Spiegelman director MYRIAD GENETICS, 320 WAKARA WAY, SALT LAKE CITY UT 84003
Jean-philippe Tripet director 1420 FIFTH AVENUE, SUITE 2600, SEATTLE WA 98101-2347